Weight Loss Drug: Half Users Quit After One Year
The Ozempic Cliff: why Half of Users Quit Weight-Loss Wonder Drug Within a Year
vienna, Austria – The buzz around GLP-1 receptor agonists (GLP-1RAs) like semaglutide, marketed under names like Ozempic adn Wegovy, has been deafening. These drugs, initially developed for diabetes, have shown remarkable effectiveness in helping peopel shed pounds by curbing appetite and boosting feelings of fullness. but a new, large-scale study is raising serious questions about the long-term viability of these “miracle” weight-loss solutions.
Presented this week at the Annual Meeting of the european Association for the Study of Diabetes (EASD) in Vienna,the research reveals a concerning trend: half of adults without diabetes in Denmark who start taking semaglutide for weight loss discontinue treatment within just one year.
Professor reimar W. Thomsen, led author of the study from Aarhus university and Aarhus University Hospital in Denmark, emphasizes the gravity of this finding. “This level of drop off is concerning because these medications aren’t meant to be a temporary quick fix,” he explains. “For them to work effectively, they need to be taken long term. All of the beneficial effects on appetite control are lost if the medication is stopped.”
The study, which analyzed data from nationwide health registries, tracked 77,310 adults (median age 50, 72% women) in Denmark who began using semaglutide for weight loss between December 1st, 2022, and October 1st, 2023. The results paint a stark picture:
* 18% stopped treatment within three months.
* 31% stopped within six months.
* 42% stopped within nine months.
* Over half (52%) stopped within one year.
While the study doesn’t delve into the specific reasons for discontinuation, the implications are significant. Weight regain is a well-documented phenomenon when these medications are stopped, suggesting that continuous use is necessary to maintain weight loss.
This raises critical questions about the accessibility and sustainability of GLP-1RA treatments. These drugs are expensive, potentially exacerbating existing health disparities, as obesity disproportionately affects marginalized racial, ethnic, and socioeconomic communities.
The findings underscore the need for a more holistic approach to weight management, one that combines medication with lifestyle changes, ongoing support, and a realistic understanding of the long-term commitment required for success. The “Ozempic cliff,” as it might be called,serves as a crucial reminder that there are no quick fixes when it comes to health,and that lasting solutions require a multifaceted and patient-centered approach.